Screener
Avalo Therapeutics AVTX Free cash flow
Discontinued — last reported Q4 '24
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The source filing: Avalo Therapeutics’s 10-K, filed March 23, 2026. Open the filing →
- Filed
- Mar 23, 2026, 7:02 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001534120-26-000011
FAQ
- What is Avalo Therapeutics's free cash flow?
- Avalo Therapeutics (AVTX) reported free cash flow of -$15.04M in Q4 2024.
- How has Avalo Therapeutics's free cash flow changed year-over-year?
- Avalo Therapeutics's free cash flow decreased by 443.9% year-over-year, from -$2.77M to -$15.04M.
- What is the long-term trend for Avalo Therapeutics's free cash flow?
- Over 2 years (2021 to 2024), Avalo Therapeutics's free cash flow has grown at a -16.9% compound annual growth rate (CAGR), from -$71.01M to -$49.06M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Avalo Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude